2030, Patients, Sleep and THC - Medical Cannabis Brief

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2030

Patients

Sleep

THC

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

JUNE 7, 2021

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. As previously disclosed, IGC submitted IGC-AD1 to the U.S.

Clinical Trials

Clinical Trials Patients THC Safety

Medical Marijuana is Being Used to Treat Dementia With Success

FloridaMarijuana.net

AUGUST 16, 2018

Dementia cannot be confirmed until a patient is deceased. Dementia is hard on the patient, and often harder on the family or caregivers. They estimate that the number of people aged 65 years and older is expected to increase from 35 million in 2000 to 71 million in 2030. million in 2030. million in 2000 to 19.5

Clinical Trials

Clinical Trials Marijuana Patients Pharmaceutical

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Medical Marijuana is Being Used to Treat Dementia With Success

Stay Connected